Sodium channel blockers - Pipeline Insight, 2025
Description
DelveInsight’s, “Sodium Channel Blockers - Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Sodium Channel Blockers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Sodium Channel Blockers: Overview
Sodium-channel blockers comprise the Class I antiarrhythmic compounds according to the Vaughan-Williams classification scheme. These drugs bind to and block the fast sodium channels that are responsible for the rapid depolarization (phase 0) of fast-response cardiac action potentials. This type of action potential is found in non-nodal, cardiomyocytes (e.g., atrial and ventricular myocytes; purkinje tissue). Because the slope of phase 0 depends on the activation of fast sodium-channels and the rapid entry of sodium ions into the cell (Figure: Na+ in), blocking these channels decreases the slope of phase 0, which also leads to a decrease in the amplitude of the action potential.
Sodium Channel Blockers cross the blood-brain barrier and act through multiple mechanisms. They inhibit the gamma-aminobutyric acid (GABA) system (primarily lidocaine), activate the sodium ouabain-sensitive current, stimulate 5-TH2C receptors, antagonize H1 receptors and block all noradrenaline activating effect. It is through these actions that adrenergic stimulation occurs. These medications in large doses are also pro-convulsant through the above mechanisms.
Medications that act by sodium channel blockade have a wide variety of clinical applications. Broadly they include Vaughn Williams Class 1 antiarrhythmics, local anesthetics, many medications used to treat neuropathic pain (including tricyclic antidepressants (TCAs)), anticonvulsants, and cocaine. Complications of sodium channel blocker toxicity include cardiogenic shock, hypotension, bradycardia or tachycardia, cardiovascular collapse, respiratory depression, encephalopathy, status epilepticus, and death.
Report Highlights
This segment of the Sodium Channel Blockers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sodium Channel Blockers Emerging Drugs
It is currently in Phase III stage of development for Tonic-clonic epilepsy and is being developed by SK biopharmaceuticals.
It is currently in Phase I stage of development for Neuropathic pain and is being developed by Biogen.
Further product details are provided in the report……..
Sodium Channel Blockers: Therapeutic Assessment
This segment of the report provides insights about the different Sodium Channel Blockers drugs segregated based on following parameters that define the scope of the report, such as:
Sodium Channel Blockers: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sodium Channel Blockers therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sodium Channel Blockers drugs.
Sodium Channel Blockers Report Insights
Current Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Sodium Channel Blockers: Overview
Sodium-channel blockers comprise the Class I antiarrhythmic compounds according to the Vaughan-Williams classification scheme. These drugs bind to and block the fast sodium channels that are responsible for the rapid depolarization (phase 0) of fast-response cardiac action potentials. This type of action potential is found in non-nodal, cardiomyocytes (e.g., atrial and ventricular myocytes; purkinje tissue). Because the slope of phase 0 depends on the activation of fast sodium-channels and the rapid entry of sodium ions into the cell (Figure: Na+ in), blocking these channels decreases the slope of phase 0, which also leads to a decrease in the amplitude of the action potential.
Sodium Channel Blockers cross the blood-brain barrier and act through multiple mechanisms. They inhibit the gamma-aminobutyric acid (GABA) system (primarily lidocaine), activate the sodium ouabain-sensitive current, stimulate 5-TH2C receptors, antagonize H1 receptors and block all noradrenaline activating effect. It is through these actions that adrenergic stimulation occurs. These medications in large doses are also pro-convulsant through the above mechanisms.
Medications that act by sodium channel blockade have a wide variety of clinical applications. Broadly they include Vaughn Williams Class 1 antiarrhythmics, local anesthetics, many medications used to treat neuropathic pain (including tricyclic antidepressants (TCAs)), anticonvulsants, and cocaine. Complications of sodium channel blocker toxicity include cardiogenic shock, hypotension, bradycardia or tachycardia, cardiovascular collapse, respiratory depression, encephalopathy, status epilepticus, and death.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sodium Channel Blockers R&D. The therapies under development are focused on novel approaches for Sodium Channel Blockers.
This segment of the Sodium Channel Blockers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sodium Channel Blockers Emerging Drugs
- Cenobamate: SK biopharmaceuticals
It is currently in Phase III stage of development for Tonic-clonic epilepsy and is being developed by SK biopharmaceuticals.
- BIIB095: Biogen
It is currently in Phase I stage of development for Neuropathic pain and is being developed by Biogen.
Further product details are provided in the report……..
Sodium Channel Blockers: Therapeutic Assessment
This segment of the report provides insights about the different Sodium Channel Blockers drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Sodium Channel Blockers
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Sodium Channel Blockers: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sodium Channel Blockers therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sodium Channel Blockers drugs.
Sodium Channel Blockers Report Insights
- Sodium Channel Blockers Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Sodium Channel Blockers drugs?
- How many Sodium Channel Blockers drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Sodium Channel Blockers?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sodium Channel Blockers therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sodium Channel Blockers and their status?
- What are the key designations that have been granted to the emerging drugs?
- Biogen
- Parion Sciences
- AlphaNavi Pharma
- Vertex Pharmaceuticals
- SK biopharmaceuticals
- UCB Biopharma
- BIIB095
- P-1037
- ANP-230
- VX-548
- Research programme: NaV1.8 inhibitor pain therapeutics
- Cenobamate
- Lacosamide
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Sodium Channel Blockers: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Sodium Channel Blockers– DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Sodium Channel Blockers companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Sodium Channel Blockers Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Cenobamate: SK biopharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- P-1037: Parion Sciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Biogen: Biogen
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Research programme: NaV1.8 inhibitor pain therapeutics: Vertex Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Sodium Channel Blockers Key Companies
- Sodium Channel Blockers Key Products
- Sodium Channel Blockers- Unmet Needs
- Sodium Channel Blockers- Market Drivers and Barriers
- Sodium Channel Blockers- Future Perspectives and Conclusion
- Sodium Channel Blockers Analyst Views
- Sodium Channel Blockers Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
